Among the targetable mutations, ROS1 rearrangement is an actionable driver oncogene, which is prevalent in approximately 1–2% of NSCLC patients globally and 2–3% among the East Asian populations [17,18,19,20]. Here, ROS1 is linked to non-small cell lung carcinoma.